Journal of Cell Science

Identification of CD23 as a functional receptor for the proinflammatory cytokine AIMP1/p43

Hyuk-Sang Kwon[1,2], Min Chul Park[1], Dae Gyu Kim[1], Kiwon Cho[3], Young Woo Park[3], Jung Min Han[1] and Sunghoon Kim[1,4,5,*]

[1]Medicinal Bioconvergence Research Center, Seoul National University, Seoul 151-742, Korea
[2]Research Laboratories, ILDONG Pharmaceutical Co., Ltd., Hwaseong 445-170, Korea
[3]Integrative Omics Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-806, Korea
[4]WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Suwon 443-270, Korea
[5]College of Pharmacy, Seoul National University, Seoul 151-742, Korea
*Author for correspondence (sungkim@snu.ac.kr)

Accepted 14 June 2012
Journal of Cell Science 125, 4620–4629
© 2012. Published by The Company of Biologists Ltd
doi: 10.1242/jcs.108209

Summary

Aminoacyl-tRNA-synthetase-interacting multifunctional protein 1 (AIMP1/p43) can be secreted to trigger proinflammatory molecules while it is predominantly bound to a cytoplasmic macromolecular protein complex that contains several different aminoacyl-tRNA synthetases. Although its activities as a secreted signaling factor have been well characterized, the functional receptor for its proinflammatory activity has not yet identified. In this study, we have identified the receptor molecule for AIMP1 that mediates the secretion of TNF-α from THP-1 monocytic cells and primary human peripheral blood mononuclear cells (PBMCs). In a screen of 499 soluble receptors we identified CD23, a known low-affinity receptor for IgE, as a high affinity binding partner of AIMP1. We found that downregulation of CD23 attenuated AIMP1-induced TNF-α secretion and AIMP1 binding to THP-1 and PBMCs. We also observed that in THP-1 and PBMCs, AIMP1-induced TNF-α secretion, mediated by CD23, involved activation of ERK1/2. Interestingly, endothelial monocyte activating polypeptide II (EMAP II), the C-terminal fragment of AIMP1 that is also known to work as a proinflammatory cytokine, was incapable of binding to CD23 and of activating ERK1/2. Therefore, identification of CD23 not only explains the inflammatory function of AIMP1 but also provides the first evidence by which the mode of action of AIMP1 can be distinguished from that of its C-terminal domain, EMAP II.

Key words: AIMP1, TNF-α, CD23, ERK1/2, EMAP II, Monocyte, Cytokine

Introduction

Aminoacyl-tRNA-synthetase-interacting multifunctional protein 1 (AIMP1; also known as p43), was identified as one of three auxiliary factors of the mammalian aminoacyl tRNA synthetase (ARS) complex (Quevillon et al., 1997). AIMP1 binds and facilitates the catalytic reaction of arginyl-tRNA synthetase (Park et al., 1999). AIMP1 is also involved in diverse physiological processes (Lee et al., 2008), including extracellular cytokine activities involving monocytes (Ko et al., 2001; Park et al., 2002a; Park et al., 2002b), endothelial cells (Park et al., 2002c), and fibroblasts (Park et al., 2005), and glucagon-like hormonal activity (Park et al., 2006). We recently reported that the intracellular physical interaction between AIMP1 and gp96 controls the ER retention of gp96, thereby preventing its extracellular presentation (Han et al., 2007).

The functional involvement of AIMP1 in the immune response was initially discovered through the finding that a polypeptide with cytokine activity called endothelial monocyte activating polypeptide II (EMAP II) (Quevillon et al., 1997; Shalak et al., 2001), comprises the C-terminal portion of AIMP1. This finding suggested that AIMP1 is an inactive precursor of EMAP II. However, subsequent investigations demonstrated that intact AIMP1 itself is secreted from intact mammalian cells and actively works as a cytokine to trigger the proinflammatory response through monocytes and macrophages (Ko et al., 2001). The secretion of intact AIMP1 is found in different types of cells including adenoma, immune cells and transfected cells (Barnett et al., 2000; Matschurat et al., 2003; Knies et al., 1998; Liu and Gottsch, 1999). It was recently shown that the cleavage of AIMP1 to EMAP II and its secretion are modulated by proteasome and arginyl-tRNA synthetase (Bottoni et al., 2007). Together, these data indicate that AIMP1 functions as a bona fide cytokine under physiological conditions.

Amongst the AIMP1-induced genes, a robust increase in the expression of TNF-α was observed (Park et al., 2002a). This AIMP1-induced TNF-α production is mediated mainly through activation of mitogen-activated protein kinases (MAPKs) relayed by phospholipase Cγ (PLCγ), protein kinase C (PKC), and nuclear factor-kappa B (NF-κB) (Ko et al., 2001; Park et al., 2002a; Park et al., 2002b). AIMP1 also increases the expression of inflammatory molecules including interleukin-8 (IL-8), monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1 (MIP-1) and IL1-β, as well as IL-12 production through the activation of NF-κB in macrophages (Kim et al., 2006) and bone marrow-derived dendritic cells (Kim et al., 2008). Elucidating the signaling mechanism through which AIMP1 induces TNF-α production is essential for understanding the physiological and pathophysiological role of AIMP1 in inflammation. Although several reports have described



Clone (plate-well)	Protein	BSA	AIMP1	Ratio (AIMP1/BSA)
A-35	CD23	0.1395	0.3157	2.2631
F-26	PLAC9	0.3864	0.4857	1.2570
G-04	CLEC10A	0.1024	0.2728	2.6641
G-17	IL20RB	0.3112	0.3192	1.0257
I-33	sFRP1	0.2558	0.3219	1.2584
J-18	TNFSF13	0.2849	0.2845	0.9986
J-50	Mock	0.0768	0.0680	0.8854

Fig. 1. Screening to detect potential AIMP1-binding receptors. (**A**) Heat map of primary screening data. Binding of soluble receptors to AIMP1 was monitored as described in Materials and Methods. The signal is indicated as the OD_{490} value and the degree of the signal is represented in the heat map from 0 (green) to 3 (red). The soluble receptor binding assay was performed using 1 μg of recombinant AIMP1 for pre-coating of the wells, along with cell culture supernatant containing each Fc-fused soluble receptor expression construct. Binding was detected using HRP-conjugated anti-hFc antibody and measuring absorbance at 490 nm. (**B**) The assay was performed using 100 ng recombinant AIMP1, or BSA as a control, in each well for pre-coating. BSA was used as the negative control and mock represents the internal control (no soluble receptor protein added). Then aliquots of cell culture supernatant containing six candidate soluble receptors were applied to the wells. Absorbance values for BSA and AIMP1 are indicated in each column. The ratio was calculated as the absorbance value of AIMP1-receptor binding divided by that of BSA-receptor binding.



Fig. 2. AIMP1 binding to CD23. (**A**) THP-1 cells were transfected with each siRNA for 48 hours and the effect of siRNA treatment on receptor candidate gene expression was analyzed by quantitative RT-PCR. The ratio was calculated as the level in candidate-receptor-siRNA-transfected cells divided by the level in control-siRNA-transfected cells. GAPDH was used as the internal control. (**B**) The effects of candidate receptor knockdown on AIMP1-induced TNF-α secretion. Data are expressed as the means ± s.e.m. (n=6). Asterisks denote significant differences from negative control siRNA (* $P<0.05$ and ** $P<0.01$, respectively). (**C**) Dose-dependent interaction of AIMP1 with Fc-fused candidate receptors. The indicated concentrations of candidate receptors (CD23, CLEC10A or sFRP1 proteins) were added to AIMP1-coated microtiter wells, and Fc-receptor bound to AIMP1 was detected with anti-Fc-conjugated peroxidase. The equilibrium dissociation constant (K_D) was determined for the interactions of AIMP1 with each candidate receptor.



Fig. 3. The effect of CD23 knockdown on AIMP1-induced TNF-α secretion and migration in THP-1 cells. THP-1 cells were treated with different concentration of biotinylated BSA and AIMP1 for 1 hour (**A**) or with 1 μg of biotinylated AIMP1 for the indicated time (**B**). Exo-AIMP1 and endo-AIMP1 are the level of externally applied biotinylated AIMP1 and endogenous AIMP1, respectively; I (input), the biotinylated BSA or AIMP1 that were used as the size controls. THP-1 cells treated with biotinylated BSA or AIMP1 were bound to streptavidin-bound Sepharose beads and harvested. Cells were lysed and the extracted proteins were subject to western blotting with horseradish-peroxidase-conjugated anti-streptavidin (top panels), anti-tubulin (third panels) and anti-AIMP1 antibody (the bottom panels). (**C**) The effect of candidate receptor knockdown on biotinylated AIMP1 binding to THP-1. Bound AIMP1 was analyzed by western blotting with streptavidin-conjugated peroxidase. The ratio represents the level of AIMP1 in control-siRNA-transfected cells divided by that in candidate receptor-siRNA-transfected cells. Tubulin was used as the internal control. (**D**) The effect of CD23 knockdown on surface CD23 expression on THP-1 cells. Integrin and HSP (heat-shock protein) were used as markers of the membrane and the cytosol, respectively. Cell surface CD23 expression was analyzed by western blotting and FACS analysis with the anti-CD23 antibody. Non-siRNA-transfected cells (NT) and control siRNA-transfected cells (siCntr) were used as negative controls. The solid purple shows the results of the control with no anti-CD23 antibody added (mock). (**E**) The effect of CD23 knockdown on AIMP1-induced TNF-α secretion. THP-1 cells were transfected with control or CD23 siRNA, treated with AIMP1 at the indicated concentrations for 3 hours, and TNF-α secretion was monitored. Data are expressed as the means ± s.e.m. (n=3). *P<0.05 and **P<0.01, significant differences from negative control siRNA. (**F**) The effect of CD23 knockdown on AIMP1-induced migration in THP-1 cells. The cell migration assay was performed using Transwell chambers with a gelatin-coated polycarbonate membrane. THP-1 cells were suspended in the upper chamber and AIMP1 (50 nM) was added to the lower chamber. Migrated cells were counted by light microscopy using high power field (HPF). Data are expressed as the means ± s.e.m. (n=3). *P<0.05 and **P<0.01, significant differences from negative control siRNA.

functional receptor candidates for AIMP1 or EMAP II (Chang et al., 2002; Hou et al., 2006; Awasthi et al., 2009), the receptor mediating AIMP1-induced TNF-α production has not yet been identified.

Macrophages and monocytes play important roles in allergic inflammation (Ohnishi et al., 2008) and the macrophages and monocytes of individuals with allergic diseases express high levels of CD23 on their cell surfaces. Cells expressing CD23 can be occupied by IgE, which equips these cells for effector functions in IgE-dependent inflammation (Conrad et al., 2007). The cross-linking of CD23-bound IgE by allergen activates cells to release inflammatory cytokines such as TNF-α, IL-6, and IL-1β (Ezeamuzie et al., 2009). The role of CD23 in inflammatory diseases was suggested by studies which showed an anti-CD23 antibody can decrease both cellular infiltration of the synovial sublining layer and destruction of cartilage in

Journal of Cell Science



Fig. 4. The effect of CD23 expression on AIMP1-induced TNF-α secretion. (**A**) The effect of CD23 overexpression on AIMP1-induced TNF-α secretion in THP-1 cells. THP-1 cells were pretreated with IL-4 (20 μg/ml) for 72 hours and some cells were also treated with anti-CD23 antibody (10 μg/ml). Cells were treated with indicated concentrations of AIMP1 for 3 hours and TNF-α secretion was monitored. Data are expressed as the means ± s.e.m. (n=3). *P<0.05 and **P<0.01, significant differences from negative control not treated with IL-4 and/or anti-CD23 antibody. (**B**) The effect of the Fc-fused sCD23 protein on AIMP1-induced TNF-α secretion. AIMP1 (2 μg) was preincubated with Fc-fused sCD23 or control protein (2 μg each) and added to THP-1 cells for 3 hours. Data are expressed as the means ± s.e.m. (n=3). *P<0.05 and **P<0.01, significant differences from negative control protein.

collagen-induced arthritis models (Rosenwasser and Meng, 2005). Accordingly, CD23-deficient mice showed delayed onset and reduced severity of collagen-induced arthritis (Kleinau et al., 1999). Thus, CD23 might be a target in the treatment of inflammatory diseases.

In this study, we show that CD23 is an AIMP1 receptor in THP-1 and primary human peripheral blood mononuclear cells (PBMCs) and plays an essential role in the AIMP1-induced immune response. We identified CD23 as an AIMP1 binding protein by screening a soluble receptor library, and showed it binds to AIMP1 with high affinity. Knockdown of CD23 suppressed cell surface binding of AIMP1, as well as AIMP1-induced ERK phosphorylation and TNF-α production. However, EMAP II, the portion of AIMP1 that mediates its association with the ARS complex, did not bind to CD23 and knockdown of CD23 had no effect on EMAP II-induced TNF-α production. These results suggest that CD23 is a specific receptor for AIMP1 and may mediate the pathophysiological activity of AIMP1 in inflammation, independent of the EMAP II.

Results

Screening to identify AIMP1-binding receptors

Potential binding partners of AIMP1 were identified by an TNF-α enzyme-linked immunosorbent assay (ELISA)-based binding assay, whereby recombinant AIMP1 was coated on a plate and reacted with 499 different soluble receptor proteins (Park et al., 2012). Among them, six soluble receptor proteins were selected as having high binding affinity for AIMP1, including CD23, CLEC10A, FRP1, IL20Rb, TNFSF13 and PLAC9, and designated as candidates AIMP1 receptors (Fig. 1A). Previously, vascular endothelial growth factor receptor 1 (VEGFR1) was identified as a receptor for EMAP II, the C-terminal fragment of AIMP1 (Awasthi et al., 2009), but AIMP1 did not interact with VEGFR1 in this screening system. To investigate the specificities of candidate receptor binding to AIMP1, we analyzed the binding ratio using recombinant AIMP1 and BSA. Among six soluble receptor proteins, only CD23 and CLEC10A showed high AIMP1/BSA binding ratios (2.2631 and 2.6641, respectively), suggesting their binding is specific for AIMP1 (Fig. 1B).

AIMP1 binds to CD23

We next determined the effects of receptor candidate knockdown on TNF-α secretion in THP-1 human monocyte cells. We first tested the effects of nine siRNAs, each targeting different receptor candidates for AIMP1. All siRNAs reduced target mRNA expression by at least 50%, as determined by quantitative RT-PCR (Fig. 2A). Among them, CD23 siRNA specifically suppressed AIMP1-induced TNF-α secretion in THP-1 cells (Fig. 2B).

To investigate whether AIMP1 specifically binds to CD23, we tested whether the binding affinity between AIMP1 and CD23 is saturable. Data were subjected to Scatchard analysis to determine maximum binding (B_{max}) and the equilibrium constant (K_D). The B_{max} and K_D were determined as 0.35 and 4.3, respectively (Fig. 2C). In contrast, CLEC10A and sFRP1 showed relatively low affinity binding for AIMP1 (K_D=159.1 nM and K_D=325.2 nM, respectively). These results suggest that CD23 is a candidate for a functional receptor for AIMP1.

CD23 mediates AIMP1 cell surface binding and AIMP1-induced TNF-α secretion

If AIMP1 binds to CD23 on the surface of THP-1 cells, the cell surface binding of AIMP1 should be closely related to the level of CD23 expression. We tested this possibility by monitoring the effect of CD23 siRNA on AIMP1 cell surface binding. To determine the optimal condition for this assay, THP-1 cells were treated with biotinylated AIMP1 at various concentrations and incubation times, and bound AIMP1 was detected with streptavidin-conjugated peroxidase or anti-AIMP1 antibody. We found that biotinylated AIMP1, but not biotinylated BSA, bound to THP-1 in a dose- and time-dependent manner (Fig. 3A,B). In addition, CD23 knockdown specifically suppressed cell surface binding of AIMP1 (Fig. 3C), which is consistent with the result showing the specific reduction of AIMP1-induced TNF-α secretion (Fig. 2B). To confirm that CD23 siRNA efficiently reduced its cell surface expression, CD23 levels were quantified by immunoblotting and fluorescence-activated cell sorting (FACS) analysis (Fig. 3D). Together, these results suggest that CD23 specifically mediates the cell surface binding of AIMP1 and AIMP1-induced TNF-α secretion in THP-1 cells.

To investigate whether AIMP1-induced TNF-α secretion is mediated by CD23, THP-1 cells were treated with different doses of recombinant biotinylated AIMP1 (50, 100 and 200 nM). We found that CD23 siRNA, but not by control siRNA, suppressed AIMP1-induced TNF-α secretion (Fig. 3E). In addition, CD23



Fig. 5. The effect of AIMP1 on ERK1/2, JNK, and AKT phosphorylation in THP-1 cells. (**A**) THP-1 cells were treated with AIMP1 (100 nM) and changes in ERK1/2, JNK and AKT phosphorylation status during the time of AIMP1 treatment were determined. (**B**) Quantitative analysis of the fold changes in the ratio of phosphorylated/total protein from A was performed using a densitometer. The changes in ERK1/2, JNK and AKT phosphorylation status were calculated as the phosphorylation level of each MAP kinase at the indicated times (5, 10, 30, 60 minutes) relative to the level at the start time (0 minute). (**C**) The effect of CD23 knockdown on AIMP1-induced ERK1/2 phosphorylation in THP-1 cells. THP-1 cells were transfected with CD23 siRNA for 48 hours followed by treatment with AIMP1 for 30 minutes. Cell lysates were analyzed using anti-CD23, -p-ERK1/2 and -ERK1/2 antibodies. (**D**) THP-1 cells were pre-incubated with U0126 or SP600125, inhibitors of ERK or JNK, respectively, for 30 minutes before treatment with AIMP1. The effects of these inhibitors on AIMP1-induced TNF-α secretion were analyzed using a TNF-α ELISA kit. Data are expressed as the means ± s.e.m. (n=3). **P<0.01, a significant difference from negative control not treated with either inhibitor.

siRNA suppressed AIMP1-induced migration of THP-1 cells in a dose-dependent manner (Fig. 3F).

Next, we confirmed whether CD23 mediates AIMP1-induced TNF-α secretion through a set of experiments where we increased or decreased the cellular levels of CD23. When THP-1 cells were treated with IL-4, a known inducer of CD23 expression (Kim et al., 2003), AIMP1 enhanced TNF-α secretion in the IL-4-treated cells than in non-treated cells (Fig. 4A). In addition, treatment with a neutralizing anti-CD23 antibody suppressed AIMP1-enhanced TNF-α secretion in IL-4-treated cells. To test whether soluble CD23 protein competed with AIMP1 for TNF-α secretion, AIMP1 was pre-incubated with CD23-Fc soluble receptor prior to addition of THP-1 cells. We found that AIMP1 induced TNF-α secretion in control Fc-treated cells, whereas CD23-Fc significantly suppressed AIMP1-induced TNF-α secretion (Fig. 4B). Although previous studies indicated that soluble CD23 activates monocytes and triggers cytokine release (Armant et al., 1995), the duration of treatment with AIMP1 and soluble CD23 was relatively short in our study, and we found that soluble CD23 itself had no effect on TNF-α secretion in THP-1 cells. Together, these results suggest that CD23 is a functional receptor for proinflammatory AIMP1 in THP-1 cells.

ERK pathway is functionally linked to CD23 for AIMP1-induced TNF-α secretion

In THP-1 cells, AIMP1 activates MAPK family members and NF-αB (Park et al., 2002a). ERK1/2 is rapidly activated in 5-10 minutes in THP-1 cells through cross-linking with an anti-CD23 antibody (Chan et al., 2010). Furthermore, JNK is associated with CD23-triggered TNF-α production in human intestinal epithelial cells (Li et al., 2006). Because MAPK family members mediate TNF-α production upon cellular exposure to LPS and other cytokines, we investigated whether AIMP1-induced CD23-mediated TNF-α secretion is mediated by MAPKs signaling pathways. We found that treating THP-1 cells with recombinant AIMP1 increased phosphorylation of ERK1/2 but not phosphorylation of JNK and AKT/protein kinase B (PKB) (Fig. 5A,B). CD23 knockdown also decreased AIMP1-induced phosphorylation of ERK1/2 (Fig. 5C). Furthermore, pre-treatment with the MEK inhibitor U0126 suppressed AIMP1-induced TNF-α secretion and ERK1/2 phosphorylation, whereas the JNK inhibitor SP600125 had no effect (Fig. 5D). Therefore, these results suggest that within the MAPK pathway, ERK family members are functionally linked to the CD23 downstream pathway for AIMP1-induced TNF-α secretion.

The central region of AIMP1 (101-192 amino acids) mediates CD23 binding and TNF-α secretion

To determine which regions of AIMP1 are involved in binding with CD23 and TNF-α secretion, several deletion derivatives of AIMP1 were used (Han et al., 2006). The deletion derivatives were purified as GST-tagged fusion proteins using a bacterial expression system, and analyzed by SDS-polyacrylamide gel electrophoresis. We compared the binding affinities of deletion AIMP1 constructs for CD23 by in vitro pull-down assay (Fig. 6A). We determined that AIMP1-(1-312), AIMP1-(1-192), AIMP1-(47-192), and AIMP1-(101-192) bound to the CD23-Fc fusion protein. In contrast, AIMP1-(1-46) and AIMP1-(193-312) did not bind the CD23-Fc fusion protein. Together, these data

Journal of Cell Science



Fig. 6. CD23 binding to the central domain of AIMP1. (**A**) A schematic drawing of the AIMP1 deletion mutant proteins used in this study and the binding affinities of the constructs for CD23. AIMP1 and its deletion mutant protein were mixed with Fc-fused sCD23 protein prior to the addition of protein A/G agarose to the mixture. Bound AIMP1 and its deletion mutant protein were investigated using the human IgG-coupled HRP. Empty vector (EV) was used as the control. Addition of Fc-fused CD23 soluble receptor was used as a loading control. (**B**) The effects of AIMP1 and its deletion mutant proteins on TNF-α induction. THP-1 cells were treated with AIMP1 and its deletion constructs, and TNF-α secretion was monitored. Empty vector (EV) was used as the control. Data are expressed as the means ± s.e.m. (n=3). (**C**) The effects of AIMP1 and its deletion mutant, AIMP1-(101-192), on TNF-α induction in CD23-knockdown THP-1 cells. THP-1 cells were transfected with control or CD23 siRNAs for 48 hours followed by treatment with 100 nM AIMP1-(1-312) or AIMP1-(101-192), and TNF-α secretion was monitored. Data are expressed as the means ± s.e.m. (n=3). *P<0.05 and **P<0.01, significant differences from negative control siRNA.

revealed that the CD23-Fc protein bound to the central region of AIMP1 (101-192 amino acids). To investigate TNF-α secretion by the AIMP1 deletion derivatives, the purified recombinant proteins were added to THP-1 cells and the levels of secreted TNF-α were determined by ELISA (Fig. 6B). We found that AIMP1-(1-312), AIMP1-(1-192), AIMP1-(47-192) and AIMP1-(101-192) showed cytokine activity. In contrast, AIMP1-(1-46) and AIMP1-(193-312) did not activate TNF-α secretion. The results suggest that AIMP1-(101-192) binds to CD23 and this region is closely linked to cytokine effect of AIMP1. To confirm that TNF-α secretion induced by the central region of AIMP1 is CD23 dependent, AIMP1-(1-312) and AIMP1-(101-192) were added to CD23 knockdown THP-1 cells and the levels of secreted TNF-α were determined (Fig. 6C). We found that CD23 knockdown suppressed AIMP1-(1-312) and AIMP1-(101-192)-induced TNF-α secretion. These results suggested that in THP-1 cells, the central region of AIMP1 (101-192 amino acids) is closely linked to the cytokine effect of AIMP1 by its binding to CD23.

AIMP1, but not EMAP II, induces TNF-α secretion via CD23

EMAP II, which is the truncated C-terminal portion of AIMP1, was first discovered as a secreted peptide in the culture medium. It was later found to possess cytokine activity including angiostatic or pro-apoptotic functions (Murray et al., 2004; Haridas et al., 2008). In this study, our data shows that AIMP1-(101-192) is a binding site for CD23 and induces TNF-α secretion. To determine whether CD23 is a specific receptor for AIMP1, even in the absence of the EMAP II portion of the protein, we directly compared the binding affinities of AIMP1 and EMAP II for CD23. In vitro pull-down assays revealed that the CD23-Fc protein bound to AIMP1 but not to EMAP II (Fig. 7A). Thus, these results indicate that the central region of AIMP1 not containing EMAP II (101-146 amino acids) mediates CD23 binding. Consistent with the previous report (Ko et al., 2001), EMAP II-induced TNF-α secretion, but the potency of EMAP II was lower than that of AIMP1. CD23 knockdown suppressed AIMP1-induced TNF-α secretion, but had no effect on EMAP II-induced TNF-α secretion (Fig. 7B). EMAP II did not activate the ERK pathway in a manner different from AIMP1 (Fig. 7C). Furthermore, pre-treatment with the MEK inhibitor U0126 did not suppress EMAP II-induced TNF-α secretion (Fig. 7D). These data suggest that in monocytic cells, AIMP1, but not EMAP II, binds to CD23 to induce TNF-α secretion, and this effect is mediated by the ERK pathway.

CD23 is a functional receptor for AIMP1 in primary immune cells

In this study, we identified CD23 as a functional receptor for AIMP1 in monocytic cells such as THP-1 cells. To confirm that

Journal of Cell Science

Journal of Cell Science



Fig. 7. The effects of AIMP1 and EMAP II on CD23-mediated TNF-α secretion. (**A**) AIMP1 or EMAP II protein was mixed with CD23 soluble receptor for 1 hour prior to the addition of protein A/G agarose to the mixture. Levels of bound AIMP1 or EMAP II were tested using the anti-AIMP1 antibody and human IgG coupled HRP. AIMP1 and EMAP II were used as loading controls. (**B**) The effect of CD23 knockdown on AIMP1 or EMAP II-induced TNF-α secretion. Data are expressed as the means ± s.e.m. (n=3). * and ** denote significant differences from negative control siRNA ($P<0.05$ and $P<0.01$, respectively). (**C**) The effect of EMAP II on ERK1/2 phosphorylation was investigated in THP-1 cells. THP-1 cells were treated with AIMP1 or EMAP II for the indicated times and the change in ERK phosphorylation was determined. (**D**) THP-1 cells were pre-incubated with U0126, which is an inhibitor of ERK, before treatment with EMAP II (100 nM) or AIMP1 (100 nM). The effects of these inhibitors on EMAP II- or AIMP1-induced TNF-α secretion were analyzed by TNF-α ELISA. Data are expressed as the means ± s.e.m. (n=3). *P=0.237 and **P=0.005, significant differences from negative control.

AIMP1 induces TNF-α production through its binding to CD23 on primary immune cells, we used primary human PBMCs to verify CD23-mediated AIMP1 binding and TNF-α production, and compared this effect with that of EMAP II. We determined the effects of CD23 knockdown on TNF-α production in PBMCs and compared it with knockdown of other known receptors of EMAP II such as VEGFR1 and CXCR3. All siRNAs reduced target mRNA expression by at least 50%, as determined by quantitative RT-PCR (Fig. 8A). Among them, CD23 siRNA specifically suppressed AIMP1-induced TNF-α production in PBMCs (Fig. 8B). In addition, CD23 knockdown suppressed the cell surface binding of AIMP1 (Fig. 8C). Consistent with the result using THP-1 cells, CD23 knockdown suppressed AIMP1-induced TNF-α secretion, but had no effect on EMAP II-induced TNF-α secretion (Fig. 8D). CD23 knockdown also decreased AIMP1-induced phosphorylation of ERK1/2, but EMAP II did not activate the ERK pathway in a manner different from AIMP1 in PBMCs (Fig. 8E). Together, these data suggest that in immune cells including PBMCs, CD23 is a functional receptor for AIMP1 and mediates AIMP1-induced TNF-α secretion in a manner different from EMAP II.

Discussion

AIMP1 is a proinflammatory cytokine that works on diverse target cells such as monocytes, endothelial cells, and fibroblasts (Park et al., 2010). To elucidate the precise mechanisms by which it functions, there have been many efforts to identify its receptor. Whereas studies have implicated the α-subunit of ATP synthase and CXCR3 as AIMP1 receptors (Chang et al., 2002; Hou et al., 2006) and VEGF receptors as EMAP II receptors in endothelial cells such as HUVECs (Awasthi et al., 2009), the precise signaling pathways that mediate the cytokine activity of AIMP1 or EMAP II in immune cells are unknown.

Here we show that CD23, a low affinity receptor for immunoglobulin E (IgE), is also a receptor for AIMP1 in immune cells. Unlike other Fc receptors for immunoglobulins, CD23 is a type II integral membrane protein with a single trans-membrane region, and is expressed on several cell types, including monocytes/macrophages, eosinophils, follicular dendritic cells, intestinal epithelial cells and B cells (Conrad et al., 2007). CD23 regulates monocyte activation and induces TNF-α production via the adhesion molecules CD11b-CD18 and CD11C-CD18 (Lecoanet-Henchoz et al., 1995). However, this signaling pathway is mediated by soluble CD23 cleaved from the membrane-bound form by ADAM10 (Weskamp et al., 2006; Lemieux et al., 2006), and its function as a receptor related to TNF-α production remains unclear.

Previous studies have shown that up-regulation of CD23 in primary human B cells and subsequent CD23-associated stimulation leads to the activation of ERK1/2, the tyrosine kinase Fyn, and the serine/threonine kinase Akt. However, Fyn and Akt were not shown to be activated by the cross-linking of CD23 in the monocytic cell lines U937 and THP-1 (Armant et al., 1995). ERK1/2 and JNK are known to be involved in TNF-α



Fig. 8. The effects of CD23 on AIMP1-induced TNF-α secretion in primary human PBMCs. (**A**) PBMCs were transfected with each siRNA for 48 hours and the effect on receptor candidate gene expression was analyzed by quantitative RT-PCR. The ratio was calculated as the level in the receptor-siRNA-transfected cells divided by the level in control-siRNA-transfected cells. GAPDH was used as the internal control. (**B**) The effects of knockdown of CD23 and other known receptors of EMAP II on AIMP1-induced TNF-α production. PBMCs transfected with each siRNA were treated with100 nM AIMP1 for 3 hours and the mRNA level of TNF-α was analyzed by quantitative RT-PCR. Data are expressed as the means ± s.e.m. ($n=3$). *$P<0.05$, a significant difference from negative control siRNA. (**C**) The effect of receptor knockdown on biotinylated AIMP1 binding to PBMCs. Bound AIMP1 was analyzed by western blotting with streptavidin-conjugated peroxidase. The ratio is the level of AIMP1 in control-siRNA-transfected cells divided by that in the receptor-siRNA-transfected cells. Tubulin was used as the internal control. (**D**) The effect of CD23 knockdown on AIMP1- or EMAP II-induced TNF-α secretion. PBMCs were transfected with CD23 siRNA before treatment with EMAP II (100 nM) or AIMP1 (100 nM). The effects of the CD23 siRNA on EMAP II- or AIMP1-induced TNF-α secretion were analyzed using the TNF-α ELISA kit. Data are expressed as the means ± s.e.m. ($n=3$). *$P=0.162$ and **$P=0.041$, a significant difference from negative control. (**E**) The effect of CD23 knockdown on AIMP1 or EMAP II-induced ERK1/2 phosphorylation in PBMCs. Cells were transfected with CD23 siRNA followed by treatment with EMAP II (100 nM) or AIMP1 (100 nM) for 30 minutes. Cell lysates were analyzed using anti-CD23, -p-ERK1/2, and -ERK1/2 antibodies. The ratio is the level of phosphorylated/total ERK1/2 protein expressed by the PBMCs treated with EMAP II or AIMP1 compared with that of untreated control cells.

production by the cross-linking of CD23 in human intestinal epithelial cells, and in these studies, p38 MAPK and NF-κB did not affect TNF-α production via CD23 (Chan et al., 2010). Here we show that in THP-1 and PBMCs, AIMP1 binds to CD23 (Fig. 3C; Fig. 8C), induces TNF-α secretion (Fig. 2B; Fig. 8B), and activates the ERK pathway (Fig. 5C; Fig. 8E). These results support the hypothesis that CD23 is a functional receptor for AIMP1.

Our observations indicate that in THP-1 and PBMCs, the AIMP1-induced signaling pathway differs from the EMAP II-induced pathway, and that CD23 is a functional receptor for AIMP1, but not EMAP II. We identified that the central domain of AIMP1 (amino acids 101-192) is a potential CD23 binding site closely related to TNF-α production (Fig. 6A,B). However, EMAP II does not possess this region nor does it bind CD23. Thus, the central region of AIMP1 not containing EMAP II (101-146 amino acids) appears to mediate CD23 binding and TNF-α secretion.

CD23 is a potentially useful diagnostic marker for a range of diseases and has been implicated in cellular and molecular processes associated with a variety of pathological states. Soluble CD23 is a potent macrophage stimulator. High levels of this molecule have been reported in rheumatoid arthritis (De Miguel et al., 2001). In addition, lumiliximab, an anti-CD23 monoclonal antibody, is a potential therapeutic antibody recently demonstrated to be safe in human and CD23 is important in orchestrating inflammation in allergic diseases and thus may represent an important therapeutic target (Poole et al., 2005). In this study, a neutralizing anti-CD23 antibody (clone MHM6) which can compete with IgE for binding to a CD23 epitope suppressed AIMP1-induced TNF-α secretion (Fig. 4A), suggesting that the AIMP1-CD23 interaction may be involved in pathophysiology of autoimmune disease.

In this study, we propose a model whereby AIMP1 induces TNF-α production through its binding to CD23 on THP-1 and PBMCs. When monocytic cells are treated with AIMP1, it binds to cell surface membrane-bound CD23 and leads to phosphorylation and activation of the ERK pathway. In turn, activation of the ERK pathway up-regulates the expression and secretion of TNF-α. AIMP1-induced TNF-α production then engages in other signaling pathways through other receptors. EMAP II, which is the C-terminal region of AIMP1, does not bind to CD23, but may be involved in inducing TNF-α production through another signaling pathway.

Materials and Methods

Cell culture and materials

THP-1 cells were obtained from American Type Culture Collection (ATCC) and grown in RPMI medium containing 10% fetal bovine serum and 50 μg/ml streptomycin and penicillin. Transwell chambers for the THP-1 cell migration assay were purchased from Corning. Anti-AIMP1 polyclonal antibody (Abcam), CD23 (Abcam), tubulin (Abcam), integrin (Santa Cruz), and HSP (Santa Cruz) antibodies were used for western blot analysis. FITC-conjugated anti-CD23 monoclonal antibody, clone MHM6 (Dako), was used for the neutralizing test and FACS analysis. IL-4, which was used as an inducer for CD23 expression, was purchased

from R&D Systems. Mouse IgG1/FITC (Dako) was used as a negative control. All siRNAs used in this study were obtained from Invitrogen. Stealth universal RNAi (Invitrogen) was used as a negative control. siRNAs were transfected by electroporation using a Microporator-mini (Digital Bio Technology).

Isolation of human peripheral blood mononuclear cells

All blood samples and procedures in this study were approved by the Seoul National University Institutional Review Board, approval number 1205/001-002, in accordance to the guidelines of National Bioethics Committee and were conducted in accordance to the Declaration of Helsinki. Peripheral blood mononuclear cells (PBMCs) were obtained from blood of healthy donors using BD Vacutainer CPT (BD Bioscience) Ficoll gradient centrifugation at 1800 ***g*** for 30 minutes at room temperature. After the separation, a thin layer of PBMCs was isolated and washed twice with RPMI 1640. The pellet was resuspended in RPMI 1640 with streptomycin. Isolated PBMCs were cultured in RPMI 1640 supplemented with 10% fetal bovine serum.

Preparation of recombinant human AIMP1 or EMAP II

Human AIMP1 and EMAP II cDNAs, encoding 312 and 166 amino acids respectively, were cloned into pET-28a (Novagen) and overexpressed in *Escherichia coli* BL21 (DE3) (Invitrogen) by induction with 0.5 mM IPTG. His-tagged AIMP1 (amino acid 1-312) and EMAP II (amino acid 148-312) were purified using nickel affinity chromatography (Invitrogen), following the manufacturer's instructions. Briefly, cells were resuspended in lysis buffer (50 mM KH_2PO_4, 500 mM NaCl, 0.2 mM EDTA, and 10% glycerol, pH 7.8) and lysed by sonication. After centrifugation at 10,000 ***g*** for 30 minutes, the lysate was loaded on a nickel affinity column. The proteins bound to the column were eluted by 300 mM imidazole buffer (300 mM imidazole, 50 mM KH_2PO_4, 500 mM NaCl, 0.2 mM EDTA, and 10% glycerol, pH 6.0). To remove the lipopolysaccharide (LPS), each protein-containing solution was loaded to polymyxin resin (Bio-Rad), incubated for 2 hours, and eluted. To further remove the residual LPS, the solution was filtered through an Acrodisc unit with a Mustang E membrane (Pall Gelman Laboratory).

Preparation of recombinant human AIMP1 deletions

The constructs of whole AIMP1, AIMP1-(1-312), and AIMP1 deletions [namely AIMP1-(1-192), AIMP1-(193-312), AIMP1-(1-47), AIMP1-(47-192), AIMP1-(101-192), AIMP1-(114-192)] were described previously (Han et al., 2006). Each of the whole AIMP1 and AIMP1-deleted constructs was expressed as a GST-tag fusion protein in *E. coli* BL21 (DE3) and purified by glutathione S bead as described previously (Ko et al., 2001). To remove lipopolysaccharide, the protein solution was dialyzed in pyrogen-free buffer (10 mM PBS, pH 6.0, 100 mM NaCl). After dialysis, the protein was loaded to polymyxin resin (Bio-Rad) pre-equilibrated with the same buffer, incubated for 20 minutes, and eluted. The concentration of the residual lipopolysaccharide (LPS) was below 20 pg/ml when determined using the Limulus Amebocyte Lysate QCL-1000 kit (BioWhittaker).

Soluble receptor binding assay

To identify the binding partner of AIMP1, soluble Fc-fused receptor proteins were used in an ELISA-based binding assay. Human cDNAs that encode extracellular region of membrane receptor except seven transmembrane proteins were subcloned into pYK602 vector, which were constructed to facilitate Fc-fused protein purification in mammalian cell, at sites for *Sfi*I restriction enzymes. These clones were transfected into HEK293 cells (ATCC). After 24 hours, transfected cells were incubated with serum-free DMEM for 3 days. Cultured media were harvested and incubated with protein A agarose bead. Bead-bound Fc-fusion proteins were eluted and dialyzed (Park et al., 2012). The MaxiSorp plates (Nunc) were coated with recombinant AIMP1 (1 μg/ml) in PBS for 12 hours at 4℃ and then blocked with 4% non-fat milk in PBS. After the Fc-fused extracellular domains of receptor proteins (1 μg/ml) were added to the plate and washed, the plates were incubated with anti-human IgG1 Fc-HRP (Thermo). The plates were washed 3 times, TMB solution was added, and the plates were read at 490 nm using a microplate reader. The equilibrium dissociation constants were calculated using ProteOn Manager^{TM} software (version 2.1) and data were evaluated using a Langmuir 1:1 binding model.

Quantitative RT-PCR analysis

Cells were seeded and incubated for 12 hours prior to transfection of siRNAs targeting receptor candidates by a microporator. To confirm siRNAs inhibitory activities, total RNAs were extracted using the RNeasy Mini Kit (QIAGEN), and quantitative RT-PCR was performed with primers specific to the receptor candidates. The following primers were used: VEGFR1, forward 5′-ATGGTCT-TTGCCTGAAATGGTGAG-3′, reverse 5′′-CTGTGAAGCCAGTGTGGTTTGC-3′; VEGFR2, forward 5′-GGAAATGACACTGGAGCCTACAAG-3′, reverse 5′-GGACCCGAGACATGGAATCACC-3′; sFRP1, forward 5′-GGCGGAGGTGA-AGCAGCAG-3′, reverse 5′-CGAAGAGCGAGCAGAGGAAGAC-3′; TNFSF13, forward 5′-CCTGGAAGCCTGGGAGAATGG-3′, reverse 5′-ATGTCACATCG-GAGTCATCCTTGG-3′; PLAC9, forward 5′-GCCGCTGCCGAACCCTTC-3′, reverse 5′-CCACGGTCTTCTCTACCATCTCC-3′; CLEC10A, forward 5′-GCT-GGTCATCATCTGTGTGGTTG-3′, reverse 5′-TGCCTGCCGTTCCTGCTTG-3′; CD23, forward 5′-TGCTGACTCTGCTTCTCCTGTG-3′, reverse 5′-TCTGCGTG-GACTGGGATTTCTG-3′; IL20Rb, forward 5′-TCTTGATGTGGAGCCCAGTG-ATC-3′, reverse 5′-TCAGGACCTTCAGTGAGTGAGC-3′; CXCR3, forward 5′-CCGACACCTTCCTGCTCCAC-3′, reverse 5′-GCTCCTGCGTAGAAGTTGAT-GTTG-3′; GAPDH, forward 5′-CGCTCTCTGCTCCTCCTGTTC-3′, reverse 5′-TTGACTCCGACCTTCACCTTCC-3′ and TNF-α, forward 5′-GGCGTGGAGCTG-AGAGATAAC-3′, reverse 5′-GGTGTGGGTGAGGAGCACAT-3′. Glyceraldehyde phosphate dehydrogenase (GAPDH) mRNA levels were used as internal controls. Human TNF-α mRNA levels were measured to verify TNF-α production by induction of AIMP1 or EMAP II.

TNF-α enzyme-linked immunosorbent assay

Cells were cultured on 12-well plates in RPMI medium with 10% FBS and 1% antibiotics for 12 hours and starved in serum-free RPMI medium for 3 hours. The indicated concentrations of AIMP1 (100 nM) were added to the serum-free medium for the indicated times, and the medium was harvested by centrifugation at 3000 ***g*** for 10 minutes. The secreted TNF-α was detected using a TNF-α ELISA Kit, according to the manufacturer's instructions (R&D Systems).

Transwell migration assay

THP-1 migration assays were performed using Transwell chambers (24-well) with polycarbonate membranes (8.0 μm pore size, Costar) as described, with slight modifications (Wakasugi and Schimmel, 1999). Briefly, the wells were coated with 0.5 mg/ml gelatin (Sigma) in PBS and allowed to air-dry. THP-1 cells were suspended in serum-free RPMI and added to the upper chamber at 5×10^5 cells per well. 50 nM of AIMP1 was placed in the lower chamber, and the cells were allowed to migrate for 10 hours at 37℃ in a 5% CO_2 incubator. After incubation, non-migrant cells were removed from the upper face of the membrane with a cotton swab. The migrant cells, which attached to the lower face, were fixed in 100% methanol and visualized by Hematoxylin (Sigma) staining. The migrant cells were counted in high power fields.

Cell binding assay

To obtain biotin-labeled AIMP1, purified His-AIMP1 (1 mg) was incubated with 0.25 mg Sulfo-NHS-SS-biotin (Pierce) in PBS for 4 hours followed by 100 nM Tris-HCl (pH 7.4) for quenching. Cells were seeded and incubated for 12 hours. After preserved cells were incubated in serum-free RPMI medium for 30 minutes, biotinylated AIMP1 was added to the culture medium and further incubated for the indicated times. The cells were washed 3 times with cold PBS, lysed in 50 mM Tris-HCl (pH 7.4) lysis buffer containing 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.2% sodium deoxycholate, 10 mM NaF, 1 mM sodium orthovanadate, 10% glycerol, and protease inhibitors, and centrifuged at 18,000 ***g*** for 15 minutes. The extracted proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and detected by streptavidin-coupled HRP (Pierce).

Fluorescence-activated cell sorting

To monitor the level of CD23 surface expression by flow cytometry, cells were transfected with specific siRNAs (50 μM) for 48 hours and then treated with IL-4 (10 ng/ml) for 72 hours. Cells were resuspended, incubated with the anti-CD23 antibody, and stained with Alexa-Fluor-488-conjugated secondary antibody (Invitrogen) in FACS buffer (PBS containing 1% BSA) for 1 hour. Cells were then washed three times with PBS and analyzed by flow cytometry using Cell Quest software (BD Biosciences).

Mitogen-activated protein kinase analysis

THP-1 cells and PBMCs were cultured on 6-well plates for 12 hours, washed twice, and starved in serum-free medium for 3 hours. Cells were incubated with the indicated concentrations of AIMP1 or EMAP II (100 nM) for the indicated times or with the indicated dose for 1 hour, and washed. The proteins were extracted with 25 mM Tris-HCl (pH 7.4) lysis buffer containing 150 mM NaCl, 1 mM EDTA, 1 mM sodium orthovanadate, 20 mM sodium fluoride, 12 mM β-glycerophosphate, 10% glycerol, 1% Triton X-100, and protease inhibitors and resolved by SDS-PAGE. Total and phosphorylated MAPKs were detected by their specific antibodies (Cell Signaling).

Pull-down assay

To confirm interactions by the in vitro pull-down assay, purified Fc-CD23 and control protein (2 μg/ml) were incubated with His-AIMP1 or EMAP II (2 μg/ml) for 1 hour. Immunoprecipitation was performed using the Fc-fused sCD23 (the soluble form of CD23 encoding the COOH-terminal 172 amino acids) or control protein using protein A/G agarose and analyzed by immunoblotting with anti-AIMP1 to detect the interaction. Thy-1 (RLE): Fc (Enzo Life Sciences) was used as a negative control.

Statistical analysis

A paired *t*-test was used to establish statistically significant differences between treatment groups. *P*-values <0.05 were considered to represent statistically

Journal of Cell Science

significant differences. Where applicable, the means ± s.e.m. of multiple measurements are reported.

Funding

This work was supported by the Global Frontier Program [grant number 2012M3A6A4054273 to S.K.]; the World Class University program of the Ministry of Education, Science and Technology [grant number R31-2008-000-10103-0 to S.K.]; and the Basic Science Research Program through the National Research Foundation of Korea [grant number 2012R1A1A2040060 to J.M.H.].

References

Armant, M., Rubio, M., Delespesse, G. and Sarfati, M. (1995). Soluble CD23 directly activates monocytes to contribute to the antigen-independent stimulation of resting T cells. *J. Immunol.* **155**, 4868-4875.

Awasthi, N., Schwarz, M. A., Verma, V., Cappiello, C. and Schwarz, R. E. (2009). Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling. *Lab. Invest.* **89**, 38-46.

Barnett, G., Jakobsen, A. M., Tas, M., Rice, K., Carmichael, J. and Murray, J. C. (2000). Prostate adenocarcinoma cells release the novel proinflammatory polypeptide EMAP-II in response to stress. *Cancer Res.* **60**, 2850-2857.

Bottoni, A., Vignali, C., Piccin, D., Tagliati, F., Luchin, A., Zatelli, M. C. and Uberti, E. C. (2007). Proteasomes and RARS modulate AIMP1/EMAP II secretion in human cancer cell lines. *J. Cell. Physiol.* **212**, 293-297.

Chan, M. A., Gigliotti, N. M., Matangkasombut, P., Gauld, S. B., Cambier, J. C. and Rosenwasser, L. J. (2010). CD23-mediated cell signaling in human B cells differs from signaling in cells of the monocytic lineage. *Clin. Immunol.* **137**, 330-336.

Chang, S. Y., Park, S. G., Kim, S. and Kang, C. Y. (2002). Interaction of the C-terminal domain of p43 and the alpha subunit of ATP synthase. Its functional implication in endothelial cell proliferation. *J. Biol. Chem.* **277**, 8388-8394.

Conrad, D. H., Ford, J. W., Sturgill, J. L. and Gibb, D. R. (2007). CD23: an overlooked regulator of allergic disease. *Curr. Allergy Asthma Rep.* **7**, 331-337.

De Miguel, S., Galocha, B., Jover, J. A., Bañares, A., Hernández-García, C., García-Asenjo, J. A. and Fernández-Gutiérrez, B. (2001). Mechanisms of CD23 hyperexpression on B cells from patients with rheumatoid arthritis. *J. Rheumatol.* **28**, 1222-1228.

Ezeamuzie, C. I., Al-Attiyah, R., Shihab, P. K. and Al-Radwan, R. (2009). Low-affinity IgE receptor (FcepsilonRII)-mediated activation of human monocytes by both monomeric IgE and IgE/anti-IgE immune complex. *Int. Immunopharmacol.* **9**, 1110-1114.

Han, J. M., Park, S. G., Lee, Y. and Kim, S. (2006). Structural separation of different extracellular activities in aminoacyl-tRNA synthetase-interacting multi-functional protein, p43/AIMP1. *Biochem. Biophys. Res. Commun.* **342**, 113-118.

Han, J. M., Park, S. G., Liu, B., Park, B. J., Kim, J. Y., Jin, C. H., Song, Y. W., Li, Z. and Kim, S. (2007). Aminoacyl-tRNA synthetase-interacting multifunctional protein 1/p43 controls endoplasmic reticulum retention of heat shock protein gp96: its pathological implications in lupus-like autoimmune diseases. *Am. J. Pathol.* **170**, 2042-2054.

Haridas, S., Bowers, M., Tusano, J., Mehojah, J., Kirkpatrick, M. and Burnham, D. K. (2008). The impact of Meth A fibrosarcoma derived EMAP II on dendritic cell migration. *Cytokine* **44**, 304-309.

Hou, Y., Plett, P. A., Ingram, D. A., Rajashekhar, G., Orschell, C. M., Yoder, M. C., March, K. L. and Clauss, M. (2006). Endothelial-monocyte-activating polypeptide II induces migration of endothelial progenitor cells via the chemokine receptor CXCR3. *Exp. Hematol.* **34**, 1125-1132.

Kim, E., Kim, S. H., Kim, S. and Kim, T. S. (2006). The novel cytokine p43 induces IL-12 production in macrophages via NF-kappaB activation, leading to enhanced IFN-gamma production in CD4+ T cells. *J. Immunol.* **176**, 256-264.

Kim, E., Kim, S. H., Kim, S., Cho, D. and Kim, T. S. (2008). AIMP1/p43 protein induces the maturation of bone marrow-derived dendritic cells with T helper type 1-polarizing ability. *J. Immunol.* **180**, 2894-2902.

Kim, J. H., Park, H. H. and Lee, C. E. (2003). IGF-1 potentiation of IL-4-induced CD23/Fc(epsilon)RII expression in human B cells. *Mol. Cells* **15**, 307-312.

Kleinau, S., Martinsson, P., Gustavsson, S. and Heyman, B. (1999). Importance of CD23 for collagen-induced arthritis: delayed onset and reduced severity in CD23-deficient mice. *J. Immunol.* **162**, 4266-4270.

Knies, U. E., Behrensdorf, H. A., Mitchell, C. A., Deutsch, U., Risau, W., Drexler, H. C. and Clauss, M. (1998). Regulation of endothelial monocyte-activating polypeptide II release by apoptosis. *Proc. Natl. Acad. Sci. USA* **95**, 12322-12327.

Ko, Y. G., Park, H., Kim, T., Lee, J. W., Park, S. G., Seol, W., Kim, J. E., Lee, W. H., Kim, S. H., Park, J. E. et al. (2001). A cofactor of tRNA synthetase, p43, is secreted to up-regulate proinflammatory genes. *J. Biol. Chem.* **276**, 23028-23033.

Lecoanet-Henchoz, S., Gauchat, J. F., Aubry, J. P., Graber, P., Life, P., Paul-Eugene, N., Ferrua, B., Corbi, A. L., Dugas, B., Plater-Zyberk, C. et al. (1995). CD23 regulates monocyte activation through a novel interaction with the adhesion molecules CD11b-CD18 and CD11c-CD18. *Immunity* **3**, 119-125.

Lee, S. W., Kim, G. and Kim, S. (2008). Aminoacyl-tRNA synthetase-interacting multifunctional protein 1/p43 and emerging therapeutic protein working at systems level. *Expert Opin. Drug Discov.* **3**, 945-957.

Lemieux, G. A., Blumenkron, F., Yeung, N., Zhou, P., Williams, J., Grammer, A. C., Petrovich, R., Lipsky, P. E., Moss, M. L. and Werb, Z. (2007). The low-affinity immunoglobulin E receptor (CD23) is cleaved by the metalloproteinase ADAM10. *J. Biol. Chem.* **282**, 14836-14844.

Li, H., Nowak-Wegrzyn, A., Charlop-Powers, Z., Shreffler, W., Chehade, M., Thomas, S., Roda, G., Dahan, S., Sperber, K. and Berin, M. C. (2006). Transcytosis of IgE-antigen complexes by CD23a in human intestinal epithelial cells and its role in food allergy. *Gastroenterol.* **131**, 47-58.

Liu, S. H. and Gottsch, J. D. (1999). Apoptosis induced by a corneal-endothelium-derived cytokine. *Invest. Ophthalmol. Vis. Sci.* **40**, 3152-3159.

Matschurat, S., Knies, U. E., Person, V., Fink, L., Stoelcker, B., Ebenebe, C., Behrensdorf, H. A., Schaper, J. and Clauss, M. (2003). Regulation of EMAP II by hypoxia. *Am. J. Pathol.* **162**, 93-103.

Murray, J. C., Heng, Y. M., Symonds, P., Rice, K., Ward, W., Huggins, M., Todd, I. and Robins, R. A. (2004). Endothelial monocyte-activating polypeptide-II (EMAP-II): a novel inducer of lymphocyte apoptosis. *J. Leukoc. Biol.* **75**, 772-776.

Ohnishi, H., Miyahara, N. and Gelfand, E. W. (2008). The role of leukotriene B(4) in allergic diseases. *Allergol. Int.* **57**, 291-298.

Park, H., Park, S. G., Kim, J., Ko, Y. G. and Kim, S. (2002a). Signaling pathways for TNF production induced by human aminoacyl-tRNA synthetase-associating factor, p43. *Cytokine* **20**, 148-153.

Park, H., Park, S. G., Lee, J. W., Kim, T., Kim, G., Ko, Y. G. and Kim, S. (2002b). Monocyte cell adhesion induced by a human aminoacyl-tRNA synthetase-associated factor, p43: identification of the related adhesion molecules and signal pathways. *J. Leukoc. Biol.* **71**, 223-230.

Park, M. C., Kang, T., Jin, D., Han, J. M., Kim, S. B., Park, Y. J., Cho, K., Park, Y. W., Guo, M., He, W. et al. (2012). Secreted human glycyl-tRNA synthetase implicated in defense against ERK-activated tumorigenesis. *Proc. Natl. Acad. Sci. USA* **109**, E640-E647.

Park, S. G., Jung, K. H., Lee, J. S., Jo, Y. J., Motegi, H., Kim, S. and Shiba, K. (1999). Precursor of pro-apoptotic cytokine modulates aminoacylation activity of tRNA synthetase. *J. Biol. Chem.* **274**, 16673-16676.

Park, S. G., Kang, Y. S., Ahn, Y. H., Lee, S. H., Kim, K. R., Kim, K. W., Koh, G. Y., Ko, Y. G. and Kim, S. (2002). Dose-dependent biphasic activity of tRNA synthetase-associating factor, p43, in angiogenesis. *J. Biol. Chem.* **277**, 45243-45248.

Park, S. G., Shin, H., Shin, Y. K., Lee, Y., Choi, E. C., Park, B. J. and Kim, S. (2005). The novel cytokine p43 stimulates dermal fibroblast proliferation and wound repair. *Am. J. Pathol.* **166**, 387-398.

Park, S. G., Kang, Y. S., Kim, J. Y., Lee, C. S., Ko, Y. G., Lee, W. J., Lee, K. U., Yeom, Y. I. and Kim, S. (2006). Hormonal activity of AIMP1/p43 for glucose homeostasis. *Proc. Natl. Acad. Sci. USA* **103**, 14913-14918.

Park, S. G., Choi, E. C. and Kim, S. (2010). Aminoacyl-tRNA synthetase-interacting multifunctional proteins (AIMPs): a triad for cellular homeostasis. *IUBMB Life* **62**, 296-302.

Poole, J. A., Meng, J., Reff, M., Spellman, M. C. and Rosenwasser, L. J. (2005). Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. *J. Allergy Clin. Immunol.* **116**, 780-788.

Quevillon, S., Agou, F., Robinson, J. C. and Mirande, M. (1997). The p43 component of the mammalian multi-synthetase complex is likely to be the precursor of the endothelial monocyte-activating polypeptide II cytokine. *J. Biol. Chem.* **272**, 32573-32579.

Rosenwasser, L. J. and Meng, J. (2005). Anti-CD23. *Clin. Rev. Allergy Immunol.* **29**, 61-72.

Shalak, V., Kaminska, M., Mitnacht-Kraus, R., Vandenabeele, P., Clauss, M. and Mirande, M. (2001). The EMAPII cytokine is released from the mammalian multisynthetase complex after cleavage of its p43/proEMAPII component. *J. Biol. Chem.* **276**, 23769-23776.

Wakasugi, K. and Schimmel, P. (1999). Highly differentiated motifs responsible for two cytokine activities of a split human tRNA synthetase. *J. Biol. Chem.* **274**, 23155-23159.

Weskamp, G., Ford, J. W., Sturgill, J., Martin, S., Docherty, A. J., Swendeman, S., Broadway, N., Hartmann, D., Saftig, P., Umland, S. et al. (2006). ADAM10 is a principal 'sheddase' of the low-affinity immunoglobulin E receptor CD23. *Nat. Immunol.* **7**, 1293-1298.